Quantcast

Latest Influenza vaccines Stories

2014-08-26 16:27:59

Latest Analysis Provides Basis for a Synthetic Ebola Blocker-Vaccine Candidate, Now Available for Testing LONDON, Aug. 26, 2014 /PRNewswire/ -- An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Ebola strains has revealed extensive conservation and sharing of specific Replikin structures back to 1976. This conservation and sharing of specific Replikin gene structures has paved the way for the development of a synthetic Ebola Blocker-Vaccine((TM)) candidate,...

2014-08-26 12:29:12

New Analysis Provides Basis for a Synthetic Dengue Blocker-Vaccine Candidate Now Available for Testing LONDON, Aug. 26, 2014 /PRNewswire/ -- An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Dengue virus strains in Pubmed, has revealed extensive conservation and sharing of specific Replikin structures back to 1944. This conservation and sharing of specific Replikin gene structures has permitted the formulation of a Synthetic Dengue Blocker-Vaccine(TM)...

2014-08-16 23:00:48

MarketReportsOnline.com adds "Global Influenza (Flu) Vaccine Market: Trends & Opportunities (2014-19)" report to its research store. Dallas, Texas (PRWEB) August 16, 2014 With the advancement in technology and discovery of new products in the field of medical sciences, vaccines have gained crucial position in the pharmaceutical industry. Vaccines are considered as the most effective health intervention ever developed, saving innumerable lives. The vaccine market is growing...

flu shot for seniors
2014-08-15 03:13:00

Craig Boerner, Vanderbilt University High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published this week in the New England Journal of Medicine (NEJM). The multi-center study enrolled 31,989 participants from 126 research centers in the U.S. and Canada during the 2011-2012 and 2012-2013 influenza seasons in the Northern...

2014-07-08 12:28:38

MERIDEN, Conn., July 8, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok. Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season's manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will enable delivery on time to...

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...

2014-06-16 08:28:43

Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic[1] BASEL, Switzerland, June 16, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines. This is the first US facility of its kind and is now approved for commercial production. The site will...

2014-05-30 12:26:02

MERIDEN, Conn., May 30, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza. UMN Pharma, which is partnered with Astellas, holds an exclusive license from Protein Sciences for the development and marketing...

2014-05-15 12:36:33

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global H1N1 Vaccines Industryhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/global_h1n1_vaccines_industry.html This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. The...

2014-03-26 12:28:56

ANN ARBOR, Mich., March 26, 2014 /PRNewswire/ -- NanoBio Corporation today announced a licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology. Under the agreement, Merck receives exclusive rights to NanoBio's NE adjuvant for use in an intranasal respiratory syncytial virus (RSV) vaccine and non-exclusive rights for use in an intranasal seasonal influenza and/or...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related